1 Pass, H. I., Vogelzang, N. J., Hahn, S. M. & Carbone, M. in Cancer Principles and Practice of Oncology 7th edn (eds De Vita, V., Hellmann, S. & Rosenberg, S.) 1687–1712 (Lippincott Williams and Wilkins, Philadelphia, 2005).

2 Carbone, M., Kratzke. R. & Testa, J. R. The pathogenesis of mesothelioma. Semin. Oncol. 29, 2–17 (2002).

3 McDonald, J. C. & McDonald, A. in Malignant Mesothelioma (eds Pass, H. I., Vogelzang, N. J. & Carbone, M.) 267–292 (Springer, New York, 2005).

4 Smith, A. H. & Wright, C. C. Chrysotile asbestos is the main cause of pleural mesothelioma. Am. J. Ind. Med. 30, 252–266 (1996).

5 Powers, A. & Carbone, M. The role of environmental carcinogens, viruses, and genetic predisposition in the pathogenesis of mesothelioma. Cancer Biol. Ther. 1, 350–355 (2002).

6 Tweedale G. & McCulloch J. Chrysophiles versus Chrysophobes. Isis 95, 239–259 (2004).

7 Yang, H. et al. TNFα inhibits asbestos-induced cytotoxicity via a NF-κB dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc. Natl Acad. Sci. USA 103, 10397–10402 (2006).

8 Liu, J. Y., Brass, D. M., Hoyle, G. W. & Brody, A. R. TNFα receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers. Am. J. Pathol. 153, 1839–1847 (1998).

9 Liu, W., Ernst, J. D. & Broaddus V. C. Phagocytosis of crocidolite asbestos induces oxidative stress, DNA damage and apoptosis in mesothelial cells. Am. J. Respir. Cell Mol. Biol. 23, 371–378 (2000).

10 Ramos Nino, M., Martinelli, M., Scapoli, L. & Mossman, B. T. in Malignant Mesothelioma (eds Pass, H. I., Vogelzang, N. J. & Carbone, M.) 21–33 (Springer, New York, 2005).

11 Xu, A., Zhou, H., Yu, D. Z. & Hei, T. K. Mechanisms of genotoxicity of crocidolite asbestos in mammalian cells: implications from mutation patterns induced by reactive oxygen species. Environ. Health Perspect. 110, 1003–1008 (2002).

12 Choe, N., Tanaka S. & Kagan E. Asbestos fibers and Interleukin-1 upregulate the formation of reactive nitrogen species in rat pleural mesothelial cells. Am. J. Respir. Cell Mol. Biol. 19, 226–236 (1998).

13 Unfried, K., Shurkes, C. & Abel, J. Distinct spectrum of mutations induced by crocidolite asbestos: clue for 8-hydroxydeoxyguanosine-dependent mutagenesis in vivo. Cancer Res. 62, 99–104 (2002).

14 Kroczynska, B. et al. Crocidolite asbestos and SV40 are co-carcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc. Natl Acad. Sci. USA 103, 14128–14133 (2006).

15 Sluis-Kremer, G. K. Asbestos disease at low exposure after long residence times. Ann. NY Acad. Sci. 643, 182–193 (1991).

16 Roushdy-Hammady, I., Siegel, J., Emri, S., Testa, J. R. & Carbone, M. A genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 357, 444–445 (2001).

17 Dogan, A. U. et al. Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res. 66, 5063–5068 (2006).

18 Bocchetta, M. et al. Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos co-carcinogenesis. Proc. Natl. Acad. Sci. USA 97, 10214–10219 (2000).

19 Cacciotti, P. et al. SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res. 65, 5256–5262 (2005).

20 Cristaudo, A. et al. SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study. Cancer Res. 65, 3049–3052 (2005).

21 Robinson, C. et al. A novel SV40 Tag transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent. Cancer Res. 66, 10786–10794 (2006).

22 Pietruska, J. R. & Kane, A. B. SV40 oncoproteins and p53 deficiency impair stress induced mesothelial cell senescence. Lung Cancer 54 (Suppl. 1), S6 (2006).

23 Baris, Y. I. et al. An outbreak of pleural mesothelioma and chronic fibrosing pleurisy in the village of Karain/Urgup in Anatolia. Thorax 33, 181–192 (1978).

24 Artvinli, M. & Baris, Y. I. Malignant mesotheliomas in a small village in the Anatolian region of Turkey: an epide-miologic study. J. Natl Cancer Inst. 63, 17–22 (1979).

25 Rohl, A. N., Langer, A. M., Monicure, G., Selikoff, I. G., Fischbein, A. Endemic pleural disease associated with exposure to mixed fibrous dust in Turkey. Science 216, 518–520 (1982).

26 Baris Y. I. et al. Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: a four-year study in the Cappadocian region of Turkey. Int. J. Cancer 39, 10–17 (1987).

27 Pooley, F. D. in Dusts and Diseases (eds Lemen, R. & Dement, J. H.) 41–44 (Pathotox, Park Forest South, Illinois, 1979).

28 Sebastien, P., Gaudichet, A., Bignon, J. & Baris, Y. I. Zeolite bodies in human lungs from Turkey. Lab. Invest. 44, 420–425 (1981).

29 Baris, Y. I., Saracci, R., Simonato, L., Skidmore, J. W. & Artvinli, M. Malignant mesothelioma and radiological chest abnormalities in two villages in Central Turkey an epidemiological and environmental investigation. Lancet 2, 984–987 (1981).

30 Wagner, J. C., Skidmore, J. W., Hill, R. J. & Griffiths, D. M. Erionite exposure and mesotheliomas in rats. Br. J. Cancer 51, 727–730 (1985).

31 World Health Organization International Agency for Research on Cancer. in IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 42, 225–239 (World Health Organization, 1987).

32 Okayasu, R., Wu, L. & Hei, T. K. Biological effects of naturally occurring and man-made fibres: in vitro cytotoxicity and mutagenesis in mammalian cells. Br. J. Cancer 79, 1319–1324 (1999).

33 Timblin, C. R., et al. Patterns of c-fos and c-jun proto-oncogene expression, apoptosis and proliferation in rat pleural mesothelial cells exposed to erionite or asbestos fibers. Toxicol. Appl. Pharmacol. 151, 88–97 (1998).

34 Peto, J., Hodgson, J. T., Matthews, F. E. & Jones, J. R. Continuing increase in mesothelioma mortality in Britain. Lancet 345, 535–539 (1995).

35 Gazdar, A., Butel, J. S. & Carbone, M. SV40 and human tumors: myth, association or causality? Nature Rev. Cancer 2, 957–964 (2002).

36 Wong, M. et al. New associations of human papillomavirus, simian virus 40, and Epstein–Barr virus with human cancer. J. Natl Cancer Inst. 94, 1832–1836 (2002).

37 Dang-Tan, T., Mahmud, A. M., Puntoni, R. & Franco, E. L. Polio vaccines, simian virus 40, and human cancer: the epidemiologic evidence for a causal association. Oncogene 23, 6535–6540 (2004).

38 Emri, S. et al. Simian virus 40 is not a cofactor in the pathogenesis of environmentally induced malignant pleural mesothelioma in Turkey. Anticancer Res. 20, 891–894, (2000).

39 De Rienzo, A. et al. Detection of SV40 DNA sequences in malignant mesothelioma specimens from the United States but not from Turkey. J. Cell. Biochem. 84, 455–459 (2002).

40 Neri, M. et al. Pleural malignant mesothelioma, genetic susceptibility and asbestos exposure. Mutation Res. 592, 36–44 (2005).

41 Fleury-Feith, J. et al. Hemizygosity of Nf2 is associated with increased susceptibility to asbestos induced peritoneal tumors. Oncogene 22, 3799–3805 (2003).

42 Uematsu, K. et al. Wnt pathway activation in mesothelioma. Cancer Res. 63, 4547–4551 (2003).

43 Jagadeeswaran, R. et al. Functonal analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 66, 352–361 (2006).

44 Karacoca, Y. et al. Environmentally-induced malignant mesothelioma and HLA distribution in Turkey. Int. J. Tuberc. Lung Dis. 2, 1017–1022 (1998).

45 Pass, H. I. et al. Asbestos exposure, pleural mesothelioma and osteopontin levels. N. Engl. J. Med. 353, 1564–1573 (2005).

46 Robinson, B. W. et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362, 1612–1616 (2003).

47 Smith, D. D. in Malignant Mesothelioma (eds Pass, H. I., Vogelzang, N. & Carbone, M.) 3–20 (Springer, New York, 2005).

48 Wagner, J. C., Sleggs, C. A. & Marchand, P. Diffuse pleural mesothelioma and asbestos exposure in northwestern Cape Providence. Br. J. Ind. Med. 17, 260–271 (1960).

49 Saffiotti, U. in Malignant Mesothelioma (eds Pass, H. I., Vogelzang, N. & Carbone, M.) 60–86 (Springer, New York, 2005).

50 Gee, J. B. L. & Bouhuys, A. Action on asbestos. N. Engl. J. Med. 285, 1317–1318 (1971).

51 Mossman, B. T., Bignon, J., Corn, M., Seaton, A., Gee, J. B. Asbestos: scientific developments and implications for public policy. Science 247, 294–301 (1990).

52 Tweedale, G. Asbestos and its lethal legacy. Nature Rev. Cancer 2, 311–315 (2002).

53 Harber, P. & Gee J. B. in Malignant Mesothelioma (eds Pass, H. I., Vogelzang, N. & Carbone, M.) 369–379 (Springer, New York, 2005).

54 Lagnese, J. A. in Malignant Mesothelioma (eds Pass, H. I., Vogelzang, N. & Carbone, M.) 821–832 (Springer, New York, 2005).

55 Kagan, E. & Jacobson, R. G. Lymphoid and plasma cell malignancies: asbestos related disorders of long latency. Am. J. Clin. Pathol. 80, 14–20 (1983).

56 Baris, B. et al. Environmental fibrous zeolite (erionite) exposure and malignant tumors other than mesothelioma. J. Environ. Pathol. Toxicol. Oncol. 15, 183–189 (1996).

57 Muscat, J. E. & Winder, E. L. Cigarette smoking, asbestos exposure, and malignant mesothelioma. Cancer Res. 52, 2263–2267 (1991).

58 Ramos-Nino, M. E. et al. Human mesothelioma cells exhibit tumor-cell specific differences in phosphatidyl-inositol 3-kinase/AKT activity that predict the efficacy of Onconase. Mol. Cancer. Ther. 4, 835–842 (2005).